7Franchini M, Montagnana M, Targher G, et al. Pathogenesis, clinical and laboratory aspects of thrombosis in cancer. J Thromb Thrombolysis, 2007, 24( 1 ) :29-38.
8Bobek V, Kovarfk J. Antitumor and antimetastatic effect of warfarin and heparins. Biomed Pharmacother, 2004, 58(4) : 213-219.
9Cunningham MS, White B, O' Donnell J. Prevention and management of venous thromboembolism in people with cancer: a review of the evidence, Clin Oncol, 2006,1 8(2) : 145-151.
10Oktar GL, Ergul EG, Kiziltepe U. Occult malignancy in patients with venous thromboembolism: risk indicators and a diagnostic screening strategy. Phlebology, 2007, 22(2):75-79.
7Kataoka H, Uchino H, Asada Y, et al, Analysis of tissue factor and tissue factor pathway inhibit or expression in human colorec- tal carcinoma cell lines and metastatic sublines to liver[J]. Int J Cancer, 1997,72(5) : 878-884.
8Khorana AA, Francis CW, Culakova E, et al. Frequency, risk fac- tors,and trends for venous thromboembolism among hospitalized Cancer patients[J]. Cancer,2007,110(10) :2339-2346.
